Are Amphetamine Salts the Same as Dextroamphetamine? The 3:1 Ratio Difference

No, they are not the same, though they are closely related. Amphetamine salts, sold as Adderall, is a 3:1 mixture of dextroamphetamine and levoamphetamine. Dextroamphetamine is a single molecule, sold alone as Dexedrine or Zenzedi. The difference matters because the levoamphetamine quarter adds norepinephrine-driven physical stimulation that dextroamphetamine alone provides less of. Same family, different composition, different side-effect profile, and different dosing in clinical practice.

The molecular difference: one drug or two?

Dextroamphetamine is a single active ingredient. Its full chemical name is dextroamphetamine sulfate, and it exists as the right-handed (d-) stereoisomer of amphetamine. One molecule, one stereochemistry, one set of effects.

Amphetamine salts is a manufactured blend. The standard formulation contains four salts in equal 25 percent parts: dextroamphetamine saccharate, dextroamphetamine sulfate, amphetamine aspartate monohydrate, and amphetamine sulfate. Because two of those four salts are dextroamphetamine and two are racemic amphetamine (half dextro, half levo), the final mixture works out to roughly 75 percent dextroamphetamine and 25 percent levoamphetamine. That is the origin of the familiar 3:1 label.

Both drugs are central nervous system stimulants. Both are Schedule II controlled substances in the United States. Both carry FDA-approved labeling for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy in most formulations. The similarity ends at the pharmacy counter.

In plain terms: amphetamine salts is a two-molecule cocktail; dextroamphetamine is one of those molecules bottled alone. Per FDA prescribing information for Adderall, the mixed salts product delivers that fixed 3:1 ratio with no way to adjust it.

Why the levoamphetamine quarter changes the physiology

The two isomers bind the same transporter proteins but with different potency. Dextroamphetamine is roughly two to three times more potent than levoamphetamine at blocking the dopamine transporter (DAT) and norepinephrine transporter (NET). It is also the isomer that drives most of the dopamine release in the striatum and prefrontal cortex, which is where ADHD symptom control largely lives.

Levoamphetamine is weaker on dopamine but comparatively stronger on peripheral norepinephrine. That means more cardiovascular stimulation per milligram: higher heart rate, more blood pressure elevation, more appetite suppression, and more of the "wired" physical feeling some patients describe. The levo isomer also has a longer elimination half-life in some pharmacokinetic studies, which can subtly stretch the tail of the dose.

This is the mechanism most thin explainers skip. The clinical difference between the two products is not really about total amphetamine exposure. It is about the ratio of central dopamine signaling to peripheral norepinephrine signaling. A patient who responds well to pure dextroamphetamine may find amphetamine salts too physically activating, and vice versa.

Quantified comparison: dosing, timing, and exposure

The two products are not milligram-for-milligram interchangeable despite what a pharmacy substitution might suggest. The levoamphetamine fraction means 10 mg of mixed salts does not equal 10 mg of dextroamphetamine in effect.

The duration numbers are approximate and vary by individual, formulation, and food intake. The 40 mg immediate-release ceiling is a labeling maximum for both, per FDA product labeling, not a universal clinical limit.

A useful reconciliation: the common claim that "Adderall is twice as strong as Dexedrine" is wrong. The correct statement is that amphetamine salts delivers about 75 percent of its mass as dextroamphetamine plus 25 percent levoamphetamine, so the effective dextroamphetamine dose of a 20 mg Adderall tablet is roughly 15 mg, not 20 mg and not 40 mg.

Time course: what happens after a single dose

The time course differs modestly because of the levo fraction. Levoamphetamine is absorbed and distributed similarly but cleared somewhat differently, so the physical stimulation can outlast the mental focus.

These are population averages. Individual half-lives of amphetamine range widely, and urine pH is a major modifier: acidic urine can cut the half-life substantially, while alkaline urine can extend it. That is why the same 20 mg dose feels different across patients.

Where the two products genuinely diverge in practice

Formulation matters as much as molecule. Dextroamphetamine is available as immediate-release tablets, extended-release Spansules, and a liquid concentrate. Amphetamine salts is available as immediate-release tablets and extended-release XR capsules. A patient who does well on Adderall XR does not automatically do well on Dexedrine Spansule, because the release curves are not identical.

Insurance and cost are real variables. Both have generic versions, and generic pricing at US pharmacies is typically in the USD 20 to USD 60 range for a 30-day supply without insurance, though this fluctuates with supply. Brand-name versions run several times higher.

Some patients report that dextroamphetamine produces less jaw clenching, less peripheral vasoconstriction, and fewer afternoon crashes. Others report the opposite: that pure dextroamphetamine feels too "mental" and that the levo fraction in mixed salts improves task initiation and physical energy. Neither report is a reliable predictor for any individual. The only way to know is a supervised trial.

Common misconceptions, corrected

Misconception one: they are identical because both are "amphetamine." The stereochemistry and the levo fraction make them pharmacologically distinct. A 2020 review of amphetamine isomer pharmacology in the journal CNS Drugs notes measurable differences in dopamine-to-norepinephrine ratio between the isomers.

Misconception two: you can swap doses one to one. Because amphetamine salts is only about 75 percent dextroamphetamine, a patient switching from 20 mg Adderall to 20 mg Dexedrine is effectively increasing their dextroamphetamine exposure by roughly a third. Prescribers usually account for this, but patients should never self-adjust.

Misconception three: the 3:1 ratio is universal. It is specific to the branded mixed-salts formulation and its generics. Other amphetamine products, including some combination and prodrug formulations such as lisdexamfetamine, have entirely different pharmacokinetics.

Misconception four: levoamphetamine is "filler." It is not. The levo isomer contributes meaningfully to norepinephrine signaling and is the reason some patients prefer mixed salts for certain symptom profiles.

A non-obvious professional caveat: because levoamphetamine drives more peripheral cardiovascular effects, patients with pre-existing hypertension, arrhythmia, or structural heart disease may be steered toward pure dextroamphetamine or a non-amphetamine option. The 2017 ACC/AHA hypertension guidelines flag stimulant-related blood pressure elevation as a clinically relevant consideration in ADHD management, per those guidelines.

Practical actions if you are comparing the two

Do not change products or doses on your own. Amphetamine products are Schedule II and switching requires a new prescription, not a pharmacy swap. The following steps are the sensible sequence.

• Ask your prescriber to document the exact product, salt form, and release mechanism on the prescription, not just "amphetamine."
• Track two weeks of objective measures before judging a switch: resting heart rate, blood pressure, sleep onset time, and appetite.
• Report physical symptoms separately from mental ones, since the levo fraction shows up mostly in the body.
• Avoid urinary alkalinizers such as large doses of vitamin C antagonists or antacids near dosing, since they alter amphetamine clearance.
• Never crush or split extended-release formulations; the release mechanism is the point of the product.
• Discuss any chest pain, palpitations, or new shortness of breath immediately with a clinician.

Red flags that warrant urgent medical contact, not a product comparison: chest pain, fainting, severe palpitations, unexplained shortness of breath, or new psychotic symptoms.

Limitations and what the evidence does not settle

Head-to-head randomized trials directly comparing dextroamphetamine and mixed amphetamine salts in ADHD are scarce. Most comparative evidence comes from pharmacokinetic studies, prescribing data, and clinical experience rather than large controlled trials. That means claims of superiority for either product are mostly individual-response observations, not established science.

The 3:1 ratio is well established. The claim that dextroamphetamine produces fewer side effects than mixed salts is plausible given the levo mechanism but not proven across populations. The claim that one works when the other fails is anecdotal and should be treated as hypothesis.

The honest clinical position: they share a parent molecule but differ in composition, peripheral load, and release profile. For any individual patient, the right choice is determined by supervised trial, not by a label comparison. That is the difference between knowing the chemistry and knowing the patient, and only one of those can be answered on a page.